Titlebook: New Anticancer Drugs; Fourth Annual Progra Stephen K. Carter,Yoshia Sakurai Book 1980 Springer-Verlag Berlin Heidelberg 1980 Drugs.Zytostat

raff淫雨霏霏

書(shū)目名稱(chēng)New Anticancer Drugs影響因子(影響力)




書(shū)目名稱(chēng)New Anticancer Drugs影響因子(影響力)學(xué)科排名




書(shū)目名稱(chēng)New Anticancer Drugs網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱(chēng)New Anticancer Drugs網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱(chēng)New Anticancer Drugs被引頻次




書(shū)目名稱(chēng)New Anticancer Drugs被引頻次學(xué)科排名




書(shū)目名稱(chēng)New Anticancer Drugs年度引用




書(shū)目名稱(chēng)New Anticancer Drugs年度引用學(xué)科排名




書(shū)目名稱(chēng)New Anticancer Drugs讀者反饋




書(shū)目名稱(chēng)New Anticancer Drugs讀者反饋學(xué)科排名

ENACT

MOAT

口訣法

Spina-Bifida

Phase II Study of Antineoplastic Agents in Japan,ffects, a satisfactory route of administration, and dose schedule are determined. Phase II is the screening in a broad spectrum of tumor types for evidence of a minimal degree of antitumor activity. Phase III is a trial to determine the degree of antitumor activity in one (or more) specific tumor ty

生命層

袖章

FIR

Continuation of Phase II Study of 1-(4-Amino-2-Methylpyrimidine-5-yl)-Methyl-3-(2-Chloroethyl)-3-Niitumor activity against various animal tumors, including L1210 mouse leukemia. The structural formulas for ACNU and the similar derivatives BCNU, CCNU, and methyl-CCNU are shown in Figure 1.I presented a paper on phase I and preliminary phase II studies of ACNU at the United States—Japan Cooperative

保存

Review of Experimental Studies on Nitrosourea Derivatives in Japan,otocin, are water-soluble compounds, and CDL-7 and EBNU are rather insoluble in water. The latter two are before clinical trials, and like other nitrosourea derivatives, have a marked antitumor activity in mouse leukemia L1210. Though GANU and MCNU are in the stage of clinical studies, it seems prem

Oscillate

The Clinical Evaluation of Analogues, IV. Nitrosoureas, the wide range of chemical structures that have been uncovered which have clinically demonstrated effective tumor cell kill. Since the ‘magic bullet’ has not yet been found, all effective anticancer drugs are limited by toxicity to normal tissues and inability to eradicate all tumor cells with the